Astellas Pharma Inc. (ALPMY)
ALPMY Stock Price Chart
Explore Astellas Pharma Inc. interactive price chart. Choose custom timeframes to analyze ALPMY price movements and trends.
ALPMY Company Profile
Discover essential business fundamentals and corporate details for Astellas Pharma Inc. (ALPMY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
29 Dec 2009
Employees
14.75K
Website
https://www.astellas.comCEO
Naoki Okamura BSc
Description
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
ALPMY Financial Timeline
Browse a chronological timeline of Astellas Pharma Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Apr 2026
Upcoming earnings on 2 Feb 2026
Upcoming earnings on 29 Oct 2025
Revenue estimate is $3.25B.
Earnings released on 30 Jul 2025
EPS came in at $0.40 surpassing the estimated $0.14 by +194.99%, while revenue for the quarter reached $3.36B , beating expectations by +3.88%.
Earnings released on 25 Apr 2025
EPS came in at $0.27 surpassing the estimated $0.15 by +84.30%, while revenue for the quarter reached $3.16B , missing expectations by -0.14%.
Earnings released on 4 Feb 2025
EPS came in at $0.30 surpassing the estimated $0.16 by +89.87%, while revenue for the quarter reached $3.40B , beating expectations by +16.92%.
Earnings released on 30 Oct 2024
EPS came in at $0.13 surpassing the estimated $0.12 by +7.53%, while revenue for the quarter reached $3.04B , beating expectations by +2.62%.
Dividend declared on 30 Sept 2024
A dividend of $0.17 per share was announced, adjusted to $0.17. The dividend was paid on 17 Dec 2024.
Earnings released on 1 Aug 2024
EPS came in at $0.24 surpassing the estimated $0.06 by +300.00%, while revenue for the quarter reached $2.95B , beating expectations by +13.12%.
Earnings released on 25 Apr 2024
EPS came in at $0.11 surpassing the estimated -$0.02 by +677.43%, while revenue for the quarter reached $2.73B , beating expectations by +9.77%.
Dividend declared on 27 Mar 2024
A dividend of $0.15 per share was announced, adjusted to $0.15. The dividend was paid on 17 Jun 2024.
Earnings released on 5 Feb 2024
EPS came in at $0.12 surpassing the estimated $0.11 by +5.63%, while revenue for the quarter reached $3.02B , beating expectations by +18.05%.
Earnings released on 1 Nov 2023
EPS came in at -$0.01 falling short of the estimated $0.17 by -105.88%, while revenue for the quarter reached $2.62B , beating expectations by +10.98%.
Dividend declared on 28 Sept 2023
A dividend of $0.17 per share was announced, adjusted to $0.17. The dividend was paid on 18 Dec 2023.
Earnings released on 1 Aug 2023
EPS came in at $0.13 falling short of the estimated $0.22 by -40.06%, while revenue for the quarter reached $2.59B , missing expectations by -1.30%.
Earnings released on 27 Apr 2023
EPS came in at $0.15 surpassing the estimated -$0.16 by +196.41%, while revenue for the quarter reached $2.67B , missing expectations by -0.92%.
Dividend declared on 30 Mar 2023
A dividend of $0.15 per share was announced, adjusted to $0.15. The dividend was paid on 16 Jun 2023.
Earnings released on 6 Feb 2023
EPS came in at $0.27 falling short of the estimated $0.29 by -8.04%, while revenue for the quarter reached $3.10B , beating expectations by +8.21%.
Earnings released on 31 Oct 2022
EPS came in at $0.28 surpassing the estimated $0.22 by +24.50%, while revenue for the quarter reached $2.63B , beating expectations by +4.11%.
Dividend declared on 29 Sept 2022
A dividend of $0.16 per share was announced, adjusted to $0.16. The dividend was paid on 15 Dec 2022.
Earnings released on 1 Aug 2022
EPS came in at $0.10 falling short of the estimated $0.16 by -36.39%, while revenue for the quarter reached $2.81B , beating expectations by +7.45%.
Earnings released on 27 Apr 2022
EPS came in at -$0.04 falling short of the estimated $0.18 by -122.59%, while revenue for the quarter reached $2.49B , missing expectations by -6.98%.
Dividend declared on 29 Mar 2022
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 15 Jun 2022.
Earnings released on 2 Feb 2022
EPS came in at $0.34 surpassing the estimated $0.30 by +15.02%, while revenue for the quarter reached $2.96B , missing expectations by -3.17%.
Earnings released on 29 Oct 2021
EPS came in at $0.20 , while revenue for the quarter reached $2.92B .
Dividend declared on 29 Sept 2021
A dividend of $0.22 per share was announced, adjusted to $0.19. The dividend was paid on 29 Sept 2021.
Earnings released on 30 Jul 2021
EPS came in at $0.15 , while revenue for the quarter reached $2.93B .
Earnings released on 27 Apr 2021
EPS came in at -$0.06 , while revenue for the quarter reached $2.79B .
Dividend declared on 29 Mar 2021
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 16 Jun 2021.
Earnings released on 29 Jan 2021
EPS came in at $0.31 , while revenue for the quarter reached $2.92B .
Earnings released on 31 Dec 2020
EPS came in at $0.31 , while revenue for the quarter reached $3.15B .
Dividend declared on 28 Sept 2020
A dividend of $0.14 per share was announced, adjusted to $0.14. The dividend was paid on 15 Dec 2020.
ALPMY Stock Performance
Access detailed ALPMY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.